These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26493768)

  • 1. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.
    Blin P; Dureau-Pournin C; Lassalle R; Abouelfath A; Droz-Perroteau C; Moore N
    Br J Clin Pharmacol; 2016 Mar; 81(3):569-78. PubMed ID: 26493768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events.
    Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG;
    Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
    Gaubert M; Resseguier N; Laine M; Bonello L; Camoin-Jau L; Paganelli F
    J Thromb Haemost; 2018 Mar; 16(3):465-473. PubMed ID: 29274198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation.
    Blin P; Dureau-Pournin C; Cottin Y; Bénichou J; Mismetti P; Abouelfath A; Lassalle R; Droz C; Moore N
    Br J Clin Pharmacol; 2019 Feb; 85(2):432-441. PubMed ID: 30423205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation.
    Pérez Cabeza AI; Bravo Marques R; Chinchurreta Capote PA; Ruiz Mateas F; Fanola CL; Rosas Cervantes G; González Correa JA; Valle Alberca A; Mesa Prado F; López Tejero S; Ruff CT
    Clin Cardiol; 2018 Sep; 41(9):1252-1258. PubMed ID: 30062699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison Between Long-Term Clinical Outcomes of Vitamin K Antagonist and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Yoshida R; Morishima I; Takagi K; Morita Y; Tsuboi H; Murohara T
    Circ J; 2018 Jul; 82(8):2016-2024. PubMed ID: 29863094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study.
    Ording AG; Horváth-Puhó E; Adelborg K; Pedersen L; Prandoni P; Sørensen HT
    Cancer Med; 2017 Jun; 6(6):1165-1172. PubMed ID: 28544489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events.
    Cordero A; Ferreiro JL; Bertomeu-González V; Rodríguez-Mañero M; Fácila L; Escribano D; Sanchez-Recalde A; Zuazola P; Ruiz-Nodar JM; González-Juanatey JR
    J Cardiovasc Pharmacol; 2021 Feb; 77(2):164-169. PubMed ID: 33351537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life cost of vitamin K antagonist treatment in patients with non-valvular atrial fibrillation in France in 2013.
    Dallongeville J; Ansolabehere X; Karusisi N; Maurel F; Van Ganse E; Le Heuzey JY
    J Med Econ; 2017 Sep; 20(9):974-981. PubMed ID: 28682153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
    Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
    Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis.
    Laville SM; Couchoud C; Bauwens M; Vacher-Coponat H; Choukroun G; Liabeuf S;
    Nephrol Dial Transplant; 2024 Sep; 39(10):1662-1671. PubMed ID: 38366954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.